145724 20260217205604.0 doi 10.3390/metabo14110618 sideral 140648 ART-2024-140648 eng Espina, Silvia Universidad de Zaragoza Unraveling the Association of Liver Steatosis and Fibrosis with Vitamin B12: A Cross-Sectional Study 2024 Access copy available to the general public Unrestricted Background: There are conflicting studies reporting both an increase and a decrease in vitamin B12 (VB12) levels in non-alcoholic fatty liver disease (NAFLD). In this study, we aimed to dissect the effects of steatosis and fibrosis on VB12. Methods: This is a cross-sectional study including all patients with a vibration-controlled transient elastography (VCTE) performed at the Hospital Miguel Servet (Zaragoza, Spain) between 2019 and 2022 for a chronic liver disease and having a recent blood test for VB12 levels. Liver fibrosis was assessed by VCTE and hepatic steatosis by ultrasonography and/or through controlled attenuation parameter (CAP). Results: 1195 patients (NAFLD n = 441, other chronic liver disease n = 754) were included. Median age was 57 years, 53% female. Patients with NAFLD had lower levels of VB12 compared to the rest of chronic liver diseases (289 vs. 313 pg/mL, p < 0.001). A significant negative correlation was observed between VB12 levels and hepatic steatosis measured by CAP (r = −0.13, p < 0.001). A significant positive correlation was observed between VB12 levels and liver stiffness in patients with NAFLD in both sexes (men r = 0.31, p < 0.001 and women r = 0.15, p = 0.016). A significant association between VB12 levels and liver fibrosis in cirrhosis stage was observed in patients with NAFLD (OR 1.06, 95% CI, 1.025–1.098, p = 0.001). Conclusion: VB12 levels were lower with greater hepatic steatosis. In NAFLD, VB12 levels were lower compared to other chronic liver diseases but their levels increased with higher liver stiffness and in cirrhosis stage. info:eu-repo/grantAgreement/ES/DGA/B03-23R info:eu-repo/grantAgreement/ES/ISCIII/PI22-01366 info:eu-repo/grantAgreement/ES/ISCIII/PMP21-00094 info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es 3.7 2024 BIOCHEMISTRY & MOLECULAR BIOLOGY 124 / 320 = 0.387 2024 Q2 T2 0.996 2024 Biochemistry 2024 Q2 Molecular Biology 2024 Q2 Endocrinology, Diabetes and Metabolism 2024 Q2 6.9 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Casas-Deza, Diego Universidad de Zaragoza (orcid)0000-0001-6883-8940 Bernal-Monterde, Vanesa Universidad de Zaragoza Royo-Esteban, Ana García-Sobreviela, Maria Pilar Calmarza, Pilar Martinez-Martinez, Ana B. Universidad de Zaragoza (orcid)0000-0002-1557-7545 Osada, Jesús Universidad de Zaragoza (orcid)0000-0002-8251-8457 Arbones-Mainar, Jose M. (orcid)0000-0002-8982-3737 1006 255 Universidad de Zaragoza Dpto. Fisiatría y Enfermería Área Enfermería 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 1002 060 Universidad de Zaragoza Dpto. Bioq.Biolog.Mol. Celular Área Bioquímica y Biolog.Mole. 14, 11 (2024), 618 [11 pp.] Metabolites 2218-1989 929633 http://zaguan.unizar.es/record/145724/files/texto_completo.pdf Versión publicada 2656551 http://zaguan.unizar.es/record/145724/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:145724 articulos driver 2026-02-17-20:46:21 ARTICLE